Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: Observations from the ESTEEM trial

European Heart Journal

Volumn 28, Issue 6, 2007, Pages 692-698

  Christersson, Christina ^a   Oldgren, Jonas ^a   Bylock, Anders ^b   Siegbahn, Agneta ^a   Wallentin, Lars ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Coaguulation activity; Direct thrombin inhibitor; Ischaemic event; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; PLACEBO; PROTHROMBIN; XIMELAGATRAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT DISEASE; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THROMBOPLASTIN TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33947316375     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl564     Document Type: Article

References (28)

1. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 2002;113:668-680.
2. Reganon E, Vila V, Martinez-Sales V, Vaya A, Aznar J. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. Haematologica 2002;87:740-745; discussion 745.
3. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
4. Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:1059-1064.
5. Fiotti N, Di Chiara A, Altamura N, Miccio M, Fioretti P, Guarnieri G, Giansante C. Coagulation indicators in chronic stable effort angina and unstable angina: relationship with acute phase reactants and clinical outcome. Blood Coagul Fibrinolysis 2002;13:247-255.
6. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-2522.
7. Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:497-505.
8. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004;24:1529-1534.
9. Frostfeldt G, Gustavsson G, Lindahl B, Nygren A, Siegbahn A, Wallentin L. Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction. Thromb Res 2002;105:193-199.
10. Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Brooks L, Griffin JH, Potthoff RF, Van de Werf F, Califf RM, Topol EJ. Effect of hirudin vs. heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J 2002;23:1202-1212.
11. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
12. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561-568.
13. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999;354:701-707.
14. Fox KA, Antman EM, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-482.
15. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
16. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797.
17. Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. J Thromb Haemost 2005;3:2245-2253.
18. Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 2002;39:109-112.
19. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90:2236-2240.
20. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999;20:1493-1502.
21. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003;90:1163-1172.
22. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758-763.
23. Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Theroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic ++ Syndromes. Eur Heart J 2000;21:1473-1481.
24. Oldgren J, Siegbahn A, Grip L, Linder R, Thygesen K, Wallentin L. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease. Thromb Haemost 2004;91:381- 387.
25. Thrombin Inhibition in Myocardial Ischemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J 1997;18:1416-1425.
26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775-782.
27. Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease. Eur Heart J 1999;20:1657-1666.
28. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, Topol EJ, Granger CB, Hochman JS. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91-101.